Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ozanezumab in amyotrophic lateral sclerosis
2012-003349-13Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of ozanezumab in amyotrophic lateral sclerosis (ALS), sponsored by GSK. Primary endpoint: Joint rank analysis of function and survival. Started Oct 2012; status: completed.
02
Drugs
ozanezumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2012-003349-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003349-13.